GlassScriptPhysician profile
Matthew Thomas Barnes
NPI 1477046894
$24,914.40
in general payments reported to CMS, 2019-2025
7 companies · $6,647 in 2025
The $6,647 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,267 · 2022: $10K · 2023: $5,805 · 2024: $1,154 · 2025: $6,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,100 · Travel and Lodging: $3,453 · Consulting Fee: $2,310 · Food and Beverage: $1,734 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,100.00 |
| Travel and Lodging | $3,453.03 |
| Consulting Fee | $2,310.00 |
| Food and Beverage | $1,734.34 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,784.65 | 2021-2025 | |
| Gilead Sciences, INC. | $10,433.04 | 2021-2025 | Epclusa |
| Braeburn INC. | $289.08 | 2025 | Brixadi |
| Indivior INC. | $263.15 | 2024-2025 | Sublocade |
| Alcon Vision LLC | $104.39 | 2022 | |
| Orexo US, INC. | $23.16 | 2025 | |
| Bausch & Lomb Americas INC. | $16.93 | 2023 | Lotemax Sm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.